To assess the relative merit of increased serum levels of @entity7 and basic fibroblastic growth factor in predicting the risk of disease progression of @entity1 with early @entity1072 we analyzed 81 Binet stage A @entity1 whose sera were taken at the time of diagnosis and evaluated for the presence of @entity7 and basic fibroblast growth factor using an enzyme-linked immunosorbent assay. Serum levels of @entity7 positively correlated with Rai sub-stages (P=0.03), peripheral @entity1503 (P=0.03), bone marrow histology (P=0.04) and @entity2262 ( @entity2262 ) (P=0.006). When dealing with basic fibroblast growth factor only a correlation with Rai sub-stages (P=0.02) could be found. Different cut-offs set on the basis of a stratification in quartiles, failed to demonstrate any correlation between serum levels of basic fibroblast growth factor and disease progression. In contrast, @entity1 with increased serum levels of @entity7 (above median value, 203 pg ml(-1)) had a three times increased risk of disease progression, although, in multivariate analysis only Rai sub-stages (P=0.0001) and lymphocyte doubling time (P=0.002) retained their prognostic significance. Low levels of @entity7 were indicative of good clinical outcome in the subgroup of @entity1 with either low (P=0.02) or high (P=0.03) @entity2262 concentration. Finally, the highest prognostic power was obtained when serum @entity7 and @entity2262 were examined in combination. Median of progression-free survival of @entity1 who had both serum @entity7 and @entity2262 higher than median value was only 13 months, in contrast median progression-free survival of @entity1 with one marker increased (i.e. above the 50th percentile) was 40 months. @entity1 with both markers below the median experienced the best clinical outcome (median progression-free survival not reached at 40 months). In conclusion, serum levels of either @entity7 or basic fibroblast growth factor are high in @entity1 with early @entity6444 , however, only @entity7 predicts behaviour of disease and helps to refine the prognosis of stage A @entity1 .

Clinicoprognostic implications of increased serum levels of XXXX and basic fibroblastic growth factor in early @entity1072 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor'] @entity2262 :: ('567', 'Gene') :: ['beta2-microglobulin', 'beta2-m'] @entity1072 :: ('MESH:D015451', 'Disease') :: ['B-cell chronic lymphocytic leukaemia'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['blood lymphocytosis'] @entity6444 :: ('MESH:D015461', 'Disease') :: ['chronic lymphocytic leukaemia']
@entity7 :: (7422,Gene) :: ['vascular endothelial growth factor']
